Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Original Article

Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis

Authors: Li Zhen, Liu Yun-hui, Diao Hong-yu, Ma Jun, Yao Yi-long

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Growing evidence demonstrates that long noncoding RNAs (lncRNAs) are involved in the progression of various cancers including glioma. Nuclear enriched abundant transcript 1 (NEAT1), an essential lncRNA for the formation of nuclear body paraspeckles, was not fully explored in glioma. We aimed to determine the expression, roles, and functional mechanisms of NEAT1 in the progression of glioma. By real-time PCR, we suggested that NEAT1 was upregulated in glioma tissues than noncancerous brain tissues. Knockdown of NEAT1 reduced glioma cell proliferation, invasion, and migration. RNA immunoprecipitation assay combined with luciferase reporter assay confirmed miR-449b-5p-specific binding to NEAT1. Furthermore, we verified that c-Met was a directly target of miR-449b-5p. Rescue assays demonstrated NEAT1 functions a molecular sponge for miR-449b-5p and leads to the upregulation of c-Met. This regulation menchaism promotes glioma pathogenesis and may provide a potential target for the prognosis and treatment of glioma.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
3.
Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, et al. European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G: Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: Central pathology review of the eortc_26981/ncic_ce.3 trial. Acta Neuropathol. 2012;123:841–52.CrossRefPubMed
4.
Wang Y, Jiang T. Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139–46.CrossRefPubMed
5.
Ohkawa Y, Momota H, Kato A, Hashimoto N, Tsuda Y, Kotani N, Honke K, Suzumura A, Furukawa K, Ohmi Y, Natsume A, Wakabayashi T, Furukawa K: Ganglioside gd3 enhances invasiveness of gliomas by forming a complex with platelet-derived growth factor receptor alpha and yes. The Journal of biological chemistry 2015.
6.
Lin JJ, Zhao TZ, Cai WK, Yang YX, Sun C, Zhang Z, Xu YQ, Chang T, Li ZY: Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition. Oncotarget 2015.
7.
8.
9.
Mercer TR, Dinger ME, Mattick JS. Long non-coding rnas: Insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed
10.
Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, Zhang A, Jia Z, Wang G, Yu S, Pu P, Dong L, Kang C: Lncrna pro fi le of glioblastoma reveals the potential role of lncrnas in contributing to glioblastoma pathogenesis. International journal of oncology 2012;40:2004–2012.
11.
Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, et al. A pituitary-derived meg3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003;88:5119–26.CrossRefPubMed
12.
Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, et al. Chinese Glioma Cooperative G: Hotair, a cell cycle-associated long noncoding rna and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-Oncology. 2013;15:1595–603.CrossRefPubMedPubMedCentral
13.
Choudhry H, Schodel J, Oikonomopoulos S, Camps C, Grampp S, Harris AL, et al. Extensive regulation of the non-coding transcriptome by hypoxia: Role of hif in releasing paused rnapol2. EMBO Rep. 2014;15:70–6.CrossRefPubMed
14.
Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann JM, et al. A transcript map for the 2.8-mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res. 1997;7:725–35.PubMedPubMedCentral
15.
Kim YS, Hwan JD, Bae S, Bae DH, Shick WA. Identification of differentially expressed genes using an annealing control primer system in stage iii serous ovarian carcinoma. BMC Cancer. 2010;10:576.CrossRefPubMedPubMedCentral
16.
Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L, et al. Inhibition of long non-coding rna neat1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer. 2014;14:693.CrossRefPubMedPubMedCentral
17.
18.
Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor pten by competing endogenous mrnas. Cell. 2011;147:344–57.CrossRefPubMedPubMedCentral
19.
Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, et al. Endogenous mirna sponge lincrna-ror regulates oct4, nanog, and sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25:69–80.CrossRefPubMed
20.
Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor- suppressive pten cernas in an oncogenic braf-induced mouse model of melanoma. Cell. 2011;147:382–95.CrossRefPubMedPubMedCentral
21.
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, et al. An extensive microrna-mediated network of rna-rna interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147:370–81.CrossRefPubMedPubMedCentral
22.
Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B: Crnde, a long-noncoding rna, promotes glioma cell growth and invasion through mtor signaling. Cancer letters 2015.
23.
Wang P, Liu YH, Yao YL, Li Z, Li ZQ, Ma J, et al. Long non-coding rna casc2 suppresses malignancy in human gliomas by mir-21. Cell Signal. 2015;27:275–82.CrossRefPubMed
24.
Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor nf-kappab1 by microrna-9 in human gastric adenocarcinoma. Mol Cancer. 2010;9:16.CrossRefPubMedPubMedCentral
25.
Tani H, Torimura M, Akimitsu N. The rna degradation pathway regulates the function of gas5 a non-coding rna in mammalian cells. PLoS One. 2013;8, e55684.CrossRefPubMedPubMedCentral
26.
Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP: Noncoding rna gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Science signaling 2010;3:ra8.
27.
Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W, et al. Long non-coding rna ccat1 promotes gallbladder cancer development via negative modulation of mirna-218-5p. Cell Death Dis. 2015;6, e1583.CrossRefPubMedPubMedCentral
28.
Hirose T, Virnicchi G, Tanigawa A, Naganuma T, Li R, Kimura H, et al. Neat1 long noncoding rna regulates transcription via protein sequestration within subnuclear bodies. Mol Biol Cell. 2014;25:169–83.CrossRefPubMedPubMedCentral
29.
Choudhry H, Albukhari A, Morotti M, Hider S, Moralli D, Smythies J, Schodel J, Green CM, Camps C, Buffa F, Ratcliffe P, Ragoussis J, Harris AL, Mole DR: Tumor hypoxia induces nuclear paraspeckle formation through hif-2alpha dependent transcriptional activation of neat1 leading to cancer cell survival. Oncogene 2014.
30.
Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, et al. The oestrogen receptor alpha-regulated lncrna neat1 is a critical modulator of prostate cancer. Nat Commun. 2014;5:5383.CrossRefPubMedPubMedCentral
31.
32.
Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, et al. Human glioma growth is controlled by microrna-10b. Cancer Res. 2011;71:3563–72.CrossRefPubMedPubMedCentral
33.
Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, et al. Micrornas/tp53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A. 2012;109:5316–21.CrossRefPubMedPubMedCentral
34.
Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ, Choi E, et al. Combining microrna-449a/b with a hdac inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer. 2012;76:171–6.CrossRefPubMed
35.
Ren XS, Yin MH, Zhang X, Wang Z, Feng SP, Wang GX, et al. Tumor-suppressive microrna-449a induces growth arrest and senescence by targeting e2f3 in human lung cancer cells. Cancer Lett. 2014;344:195–203.CrossRefPubMed
Metadata
Title
Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis
Authors
Li Zhen
Liu Yun-hui
Diao Hong-yu
Ma Jun
Yao Yi-long
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3843-y

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

Gab1 regulates SDF-1-induced progression via inhibition of apoptosis pathway induced by PI3K/AKT/Bcl-2/BAX pathway in human chondrosarcoma

Original Article

The long noncoding RNA, EGFR-AS1, a target of GHR, increases the expression of EGFR in hepatocellular carcinoma

Original Article

Histological mixed-type as an independent risk factor for nodal metastasis in submucosal gastric cancer

Original Article

Prognostic value of long noncoding RNA MALAT1 in various carcinomas: evidence from nine studies

Original Article

Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer

Review

Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits